Published on 13 Mar 2024 on Zacks via Yahoo Finance

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

Lexicon Pharmaceuticals, Inc. LXRX announced data from a new post hoc analysis of its phase III inTandem3 study that evaluated sotagliflozin for the treatment of patients with type 1 diabetes and chronic kidney disease (CKD).

Data from the new post hoc analysis showed that treatment with sotagliflozin improved glycemic control in the given patient population, while also successfully lowering A1C (blood sugar levels), body weight and systolic blood pressure.

Per the press release, in a subgroup of patients with type 1 diabetes and CKD, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts, relative to placebo. Treatment with sotagliflozin was also associated with the same risks of severe hypoglycemia between the two cohorts.